PT Diagnos Laboratorium Utama Tbk Stocks

IDR 268Last Updated 29.04.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

IDR 20.70M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
IDR 268
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers clinical pathology laboratory tests comprising hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology, microbiology, and anatomical pathology; anatomical pathology laboratory tests for examination of tissues and/or body fluids; and genomics laboratory tests comprising non-invasive prenatal testing, preimplantation genetic testing for aneuploidy services, and preimplantation genetic testing for monogenic diseases services. It also offers homecare health services for health checks that can be done at home; corporate health services; and covid-19 check-up services, as well as health care activities managed by the government and the private sector, such as pharmacy warehouses, eye banks, blood banks, sperm banks, organ transplant banks, and other health care services. The company was founded in 2007 and is headquartered in Jakarta Pusat, Indonesia.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks